Please assess the completion status of the following clinical trial:

Trial Title: Probiotic Treatment in Adult Obsessive-Compulsive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a principal diagnosis of OCD (DSM 5) according to the MINI with a Y-BOCS score of ≥20~2. The ability to comprehend and satisfactorily comply with protocol requirements~3. Written informed consent given prior to beginning of the study.~4. Current use of any psychotropic agent is permitted given that that individual has been on a stable dose for at least 8 weeks.~Exclusion Criteria:~1. Participants with current Major Depressive Disorder.~2. A MADRS score ≥ 18. Patients with significant suicidal ideation (MADRS item 10 ≥ 3) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.~3. Individuals with current autoimmune disorders (rheumatoid arthiritis, systemic lupus erythematosus, multiple sclerosis, etc.), inflammatory bowel disease, diabetes.~4. Current use of herbal psychoactive treatments i.e. St. John's Wort, Kava Kava, Chamomile Extract, Valeria. Past use is permitted if treatment ended 3 months prior to entering the study and stool sampling.~5. Participants receiving current psychotherapy, including cognitive behavioural therapy for an anxiety or mood disorder. Past psychotherapy is permitted if treatment ended 3 months prior to entering the study and stool sampling.~6. Patients who currently fulfill criteria for a lifetime history of bipolar disorder, history of drug abuse, a history of schizophrenia or other psychotic disorders, delirium, dementia and amnesic and other cognitive disorders, or are in a current agitated state.~7. Patients meeting criteria for current substance use disorder.~8. Antibiotic or probiotic use within 8 weeks of entering the study and stool sampling.~9. Reports frequent consumption of foods rich in/enriched with probiotics (yogurt etc).~10. Individuals with immune-compromised conditions (i.e. AIDS, lymphoma) or those undergoing long-term corticosteroid treatment.~11. Individuals with a soy or lactose allergy.~12. Female participants must not be breastfeeding, pregnant or seeking to get pregnant during the course of this study.~13. History of allergic response to probiotics or any other related drugs.~14. Currently physically unwell including experiencing nausea, fever, vomiting, abdominal pain, bloody diarrhea.~15. Individuals with prosthetic heart valves, or a history of valvular heart disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval